Articles

Non-vaccine approaches for tackling malaria have made an impact in reducing the number of malaria cases and deaths but a vaccine would help tremendously towards malaria elimination. New sources of funding such as those from the Bill and Melinda Gates Foundation, pharmaceutical companies and oil companies in the last decade has enabled rapid advances in malaria vaccine development. We are likely to see the RTS,S/AS01 vaccine to be licensed for use in the next few years despite its low efficacy.

by Litt-Yee Hiew Our immune system is naturally gifted with remarkable specificity, potency and memory. So far, no pharmacological treatment for any diseases could possibly provide comparable level of safety, efficacy and lasting effects as the human immune response. In the treatment of cancer, after …

Bites from venomous snakes can lead to snakebite envenomation (not poisoning), and antivenom is the only definitive therapy to date. Antivenoms used in current clinical practices are derived from antibodies of animals (e.g. horses) that have been immunised with one or a mix of snake venoms. However, the production of these biologics is highly costly, and there is no universal antivenom, as the effectiveness is limited by the different snake species and their geographical locality. The production and use of antivenoms can be optimised by unravelling the complexity of venoms, especially their immunogenicity and the dynamics-kinetics of venom-antivenom interplay.

Breakdown of the amino acid tryptophan through the kynurenine pathway impacts a plethora of immunological processes, ranging from the starvation of invading bacteria to the induction of immunotolerance and the modulation of neurological diseases.